Cardiovascular Disease
Many older adults still use aspirin for CVD prevention, contrary to clinical guidance
Almost one-third of adults aged 60 years and older without CVD regularly used aspirin for primary prevention in 2021, contrary to guidance from medical organizations, a study showed.
Study: Rates of potassium-based sodium substitutes higher in food with ‘reduced sodium’
Rates of potassium-based sodium substitutes were higher in products with a “reduced sodium” claim compared with other sodium content claim categories, according to published data.
‘This is going to take all of us’: Creative partnerships can reduce cardiometabolic risk
BOSTON — Lowering cardiovascular risk for people with type 2 diabetes requires effort from far beyond the clinician’s office, leveraging creative community partnerships that address social determinants of health, according to a speaker.
Hot flash severity may predict metabolic-associated liver disease
BOSTON — Midlife women reporting bothersome hot flashes are more likely to receive a diagnosis of metabolic dysfunction-associated steatotic liver disease regardless of hormone therapy use, according to a speaker.
Single excess weight measurement ‘does not seal one’s fate’ for heart-related events
BOSTON — Younger adults are at greater cardiovascular disease risk if they have obesity for 10 years, but a single excess weight measurement does not predict risk for heart-related events over time, according to data presented at ENDO 2024.
Adults with class II to III obesity may have increased cardiac outcomes
Adults with class II to III obesity may have an increased risk for poor cardiac outcomes but not kidney risk after adjusting for potential confounders, according to multicenter data.
Regular fish oil use may pose cardiovascular risk in those with no prior CVD
Regular use of fish oil supplements was tied to an increased risk of stroke and atrial fibrillation in adults with no prior CVD, according to results of a large prospective cohort study published in BMJ Medicine.
Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk
Use of the drug semaglutide in patients with type 2 diabetes significantly reduced the risk of major kidney disease events, cardiovascular outcomes and all-cause mortality vs. placebo, newly published data show.
Step- and time-based exercises equally beneficial in reducing CVD, mortality risks
Both step counts and time-based physical activity reduced the risks of death and CVD among women aged 62 years and older, a study in JAMA Internal Medicine showed.
Men at higher risk for diabetes-related complications than women
Men were at greater risk for several complications associated with type 1 and type 2 diabetes compared with women, according to results published in the Journal of Epidemiology & Community Health.